VCYT Q1 2020 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena

VCYTVeracyte, Inc.

$3B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$31M+5.4% YoY

Gross Profit

$19M60.7% margin

Operating Income

-$12M-39.2% margin

Net Income

-$12M-37.6% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

+4.7%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$6M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$267M

Total Liabilities

$37M

Stockholders' Equity

$230M

Cash & Equivalents

$153M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$31M	$30M	+5.4%
Gross Profit	$19M	$21M	-10.2%
Operating Income	-$12M	-$2M	-490.2%
Net Income	-$12M	-$2M	-511.2%

Revenue Segments

Testing

$38M86%

Product

$5M12%

Biopharmaceutical

$1M3%